Lipidomics Revealed Idiopathic Pulmonary Fibrosis-Induced Hepatic Lipid Disorders Corrected with Treatment of Baicalin in a Murine Model

AAPS Journal

Volumn 17, Issue 3, 2015, Pages 711-722

  Hu, Changfeng ^a   Wang, Yiqi ^a   Fan, Yongsheng ^a   Li, Haichang ^a   Wang, Chunyan ^b   Zhang, Jida ^a   Zhang, Shuijuan ^a   Han, Xianlin ^a,b   Wen, Chengping ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b BURNHAM INSTITUTE   (United States)

Author keywords

baicalin; hepatic lipidome; idiopathic pulmonary fibrosis; multidimensional mass spectrometry; shotgun lipidomics

Indexed keywords

BAICALIN; DEXAMETHASONE; FLAVONOID; GLUCOCORTICOID; LIPID;

ANIMAL; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; FATTY LIVER; IDIOPATHIC PULMONARY FIBROSIS; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER DISEASES; MALE; MOUSE; PATHOLOGY;

ANIMALS; DEXAMETHASONE; FATTY LIVER; FLAVONOIDS; GLUCOCORTICOIDS; IDIOPATHIC PULMONARY FIBROSIS; LIPIDS; LIVER DISEASES; MALE; MICE; MICE, INBRED ICR;

EID: 84939980310     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9714-4     Document Type: Article

References (58)

1. Society AT. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.
2. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.
3. Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc. 1998;73:1085–101.
4. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264–9.
5. Cooper Jr JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–40.
6. Alder S, Shimaoka K, Tsukada Y. Bleomycin toxicity. J Am Med Assoc. 1976;235:2814.
7. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65:81–94.
8. MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax. 1995;50 Suppl 1:S53–8.
9. Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 2002;162:225–31.
10. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol. 2000;157:177–87.
11. Cortijo J, Cerda-Nicolas M, Serrano A, Bioque G, Estrela JM, Santangelo F, et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J. 2001;17:1228–35.
12. Oury TD, Thakker K, Menache M, Chang LY, Crapo JD, Day BJ. Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol. 2001;25:164–9.
13. Daba MH, Abdel-Aziz AA, Moustafa AM, Al-Majed AA, Al-Shabanah OA, El-Kashef HA. Effects of L-carnitine and ginkgo biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosis. Pharmacol Res. 2002;45:461–7.
14. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362–82.
15. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond). 1999;96:513–23.
16. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23–43.
17. Hill Jr RB. Fatal fat embolism from steroid-induced fatty liver. N Engl J Med. 1961;265:318–20.
18. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond). 2005;2:3.
19. Diamant S, Shafrir E. Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids. Eur J Biochem. 1975;53:541–6.
20. Wang CN, McLeod RS, Yao Z, Brindley DN. Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol. 1995;15:1481–91.
21. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.
22. Gong LK, Li XH, Wang H, Zhang L, Chen FP, Cai Y, et al. Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol. 2005;96:537–44.
23. Lin CC, Shieh DE. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 1996;24:31–6.
24. Nagashima S, Hirotani M, Yoshikawa T. Purification and characterization of UDP-glucuronate: baicalein 7-O-glucuronosyltransferase from Scutellaria baicalensis Georgi. cell suspension cultures. Phytochemistry. 2000;53:533–8.
25. Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta. 1999;1472:643–50.
26. Shen YC, Chiou WF, Chou YC, Chen CF. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol. 2003;465:171–81.
27. Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of the cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev. 2005;24:367–412.
28. Yang K, Cheng H, Gross RW, Han X. Automated lipid identification and quantification by multi-dimensional mass spectrometry-based shotgun lipidomics. Anal Chem. 2009;81:4356–68.
29. Han X, Yang K, Gross RW. Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom Rev. 2012;31:134–78.
30. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 1979;120:893–9.
31. Cheng H, Guan S, Han X. Abundance of triacylglycerols in ganglia and their depletion in diabetic mice: implications for the role of altered triacylglycerols in diabetic neuropathy. J Neurochem. 2006;97:1288–300.
32. Han X, Yang K, Gross RW. Microfluidics-based electrospray ionization enhances intrasource separation of lipid classes and extends identification of individual molecular species through multi-dimensional mass spectrometry: development of an automated high throughput platform for shotgun lipidomics. Rapid Commun Mass Spectrom. 2008;22:2115–24.
33. Han X, Gross RW. Shotgun lipidomics: multi-dimensional mass spectrometric analysis of cellular lipidomes. Expert Rev Proteomics. 2005;2:253–64.
34. Han X, Yang K, Yang J, Fikes KN, Cheng H, Gross RW. Factors influencing the electrospray intrasource separation and selective ionization of glycerophospholipids. J Am Soc Mass Spectrom. 2006;17:264–74.
35. Wang M, Han RH, Han X. Fatty acidomics: global analysis of lipid species containing a carboxyl group with a charge-remote fragmentation-assisted approach. Anal Chem. 2013;85:9312–20.
36. Wang M, Hayakawa J, Yang K, Han X. Characterization and quantification of diacylglycerol species in biological extracts after one-step derivatization: a shotgun lipidomics approach. Anal Chem. 2014;86:2146–55.
37. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292:C33–44.
38. Schlame M, Ren M, Xu Y, Greenberg ML, Haller I. Molecular symmetry in mitochondrial cardiolipins. Chem Phys Lipids. 2005;138:38–49.
39. Schlame M, Ren M. Barth syndrome, a human disorder of cardiolipin metabolism. FEBS Lett. 2006;580:5450–5.
40. He Q, Han X. Cardiolipin remodeling in diabetic heart. Chem Phys Lipids. 2014;179:75–81.
41. Kiebish MA, Bell R, Yang K, Phan T, Zhao Z, Ames W, et al. Dynamic simulation of cardiolipin remodeling: greasing the wheels for an interpretative approach to lipidomics. J Lipid Res. 2010;51:2153–70.
42. Mejia EM, Nguyen H, Hatch GM. Mammalian cardiolipin biosynthesis. Chem Phys Lipids. 2014;179:11–6.
43. Gonzalvez F, Gottlieb E. Cardiolipin: setting the beat of apoptosis. Apoptosis. 2007;12:877–85.
44. Alvaro D, Cantafora A, Attili AF, Ginanni Corradini S, De Luca C, Minervini G, et al. Relationships between bile salts hydrophilicity and phospholipid composition in bile of various animal species. Comp Biochem Physiol B. 1986;83:551–4.
45. Perez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta. 2008;1778:1676–95.
46. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112–24.
47. Cole LK, Vance JE, Vance DE. Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta. 1821;2012:754–61.
48. Kyo R, Nakahata N, Sakakibara I, Kubo M, Ohizumi Y. Baicalin and baicalein, constituents of an important medicinal plant, inhibit intracellular Ca2+ elevation by reducing phospholipase C activity in C6 rat glioma cells. J Pharm Pharmacol. 1998;50:1179–82.
49. Zhang X, Feng G, Jiang J, Tian H, Chen L, Cai Y, et al. Effect of baicalin and octreotide on the expression levels of P-selectin protein in multiple organs of rats with severe acute pancreatitis. J Gastroenterol Hepatol. 2009;24:1753–62.
50. Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res. 2008;49:1377–87.
51. Gaspar ML, Aregullin MA, Jesch SA, Nunez LR, Villa-Garcia M, Henry SA. The emergence of yeast lipidomics. Biochim Biophys Acta. 2007;1771:241–54.
52. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000;10:73–80.
53. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal. 2008;20:1010–8.
54. Kolesnick RN, Goni FM, Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J Cell Physiol. 2000;184:285–300.
55. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–52.
56. Venkatesan S, Rideout JM, Simpson KJ. Microsomal delta 9, delta 6 and delta 5 desaturase activities and liver membrane fatty acid profiles in alcohol-fed rats. Biomed Chromatogr. 1990;4:234–8.
57. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004;37:1499–507.
58. Han X, Gross RW. Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem. 2001;295:88–100.